DE69533366D1 - Radioaktivmarkierte annexin-galaktose-cluster konjugate - Google Patents

Radioaktivmarkierte annexin-galaktose-cluster konjugate

Info

Publication number
DE69533366D1
DE69533366D1 DE69533366T DE69533366T DE69533366D1 DE 69533366 D1 DE69533366 D1 DE 69533366D1 DE 69533366 T DE69533366 T DE 69533366T DE 69533366 T DE69533366 T DE 69533366T DE 69533366 D1 DE69533366 D1 DE 69533366D1
Authority
DE
Germany
Prior art keywords
galactos
annexin
radioactively marked
cluster conjugates
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69533366T
Other languages
English (en)
Other versions
DE69533366T2 (de
Inventor
Louis J Theodore
Sudhakar Kasina
John M Reno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1995/000953 external-priority patent/WO1995019791A1/en
Priority claimed from PCT/US1995/007599 external-priority patent/WO1995034315A1/en
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of DE69533366D1 publication Critical patent/DE69533366D1/de
Application granted granted Critical
Publication of DE69533366T2 publication Critical patent/DE69533366T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/087—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE69533366T 1994-12-07 1995-12-06 Radioaktivmarkierte annexin-galaktose-cluster konjugate Expired - Lifetime DE69533366T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35165394A 1994-12-07 1994-12-07
US351653 1994-12-07
WOPCT/US95/00953 1995-01-23
PCT/US1995/000953 WO1995019791A1 (en) 1994-01-24 1995-01-23 Radiolabeled annexins
PCT/US1995/007599 WO1995034315A1 (en) 1994-06-16 1995-06-13 Radiolabeled annexin-galactose conjugates
WOPCT/US95/07599 1995-06-13
PCT/US1995/015851 WO1996017618A1 (en) 1994-12-07 1995-12-06 Radiolabeled annexin-galactose cluster conjugates

Publications (2)

Publication Number Publication Date
DE69533366D1 true DE69533366D1 (de) 2004-09-16
DE69533366T2 DE69533366T2 (de) 2005-08-04

Family

ID=27377832

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69533366T Expired - Lifetime DE69533366T2 (de) 1994-12-07 1995-12-06 Radioaktivmarkierte annexin-galaktose-cluster konjugate

Country Status (4)

Country Link
EP (1) EP0799050B1 (de)
CA (1) CA2206274C (de)
DE (1) DE69533366T2 (de)
WO (1) WO1996017618A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2180555C (en) * 1994-01-24 2004-12-14 Sudhakar Kasina Radiolabeled annexins
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
CA2239996C (en) 1995-12-07 2005-10-04 Bristol-Myers Squibb Company A method of applying a mixture of two liquid components
DE69838811T2 (de) 1997-04-30 2008-10-30 The Board Of Trustees Of The Leland Stanford Junior University, Stanford Verfahren zur darstellung von abgestorbenen zellen in-vivo
ES2188202T3 (es) 1998-07-13 2003-06-16 Univ Texas Metodos de tratamiento para el cancer usando conjugados terapeuticos que se enlazan con aminofosfolipidos.
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
EP1096955B9 (de) 1998-07-13 2006-07-05 Board of Regents, The University of Texas System Verwendung von antikörper gegen aminophospholipide zur krebsbehandlung
US6323313B1 (en) 1999-06-01 2001-11-27 The University Of Washington Annexin derivative with endogenous chelation sites
WO2002082044A2 (en) 2001-04-03 2002-10-17 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
US6843980B2 (en) 2001-04-03 2005-01-18 Theseus Imaging, Corp. Methods for using annexin for detecting cell death in vivo and treating associated conditions
US7589061B2 (en) 2001-04-23 2009-09-15 Mallinckrodt Inc. Tc and Re labeler radioactive glycosylated octreotide derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
DE4021979A1 (de) * 1989-07-15 1991-01-31 Boehringer Ingelheim Int Verfahren zur reinigung von annexinen
DE3937607A1 (de) * 1989-11-11 1991-05-16 Boehringer Ingelheim Int Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen
WO1991009628A1 (de) * 1989-12-27 1991-07-11 Boehringer Ingelheim International Gmbh Verwendung eines antikoagulant als diagnostikum
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
US5552525A (en) * 1991-02-08 1996-09-03 Diatech Inc. Technetium-99m labeled peptides for imaging inflammation
WO1992019279A1 (en) * 1991-05-09 1992-11-12 Board Of Regents Of The University Of Washington Phospholipid-targeted thrombolytic agents
US5371184A (en) * 1992-02-05 1994-12-06 Mallinckrodt Medical, Inc. Radiolabelled peptide compounds
WO1995034315A1 (en) * 1994-06-16 1995-12-21 Neorx Corporation Radiolabeled annexin-galactose conjugates

Also Published As

Publication number Publication date
CA2206274A1 (en) 1996-06-13
CA2206274C (en) 2009-06-30
EP0799050A1 (de) 1997-10-08
EP0799050B1 (de) 2004-08-11
WO1996017618A1 (en) 1996-06-13
EP0799050A4 (de) 1998-06-03
DE69533366T2 (de) 2005-08-04

Similar Documents

Publication Publication Date Title
DE69513688D1 (de) Befestigungslasche
DE69530472D1 (de) Kombinationswaage
DE69522636D1 (de) Kombinationswaage
DE69510614T2 (de) Supraleitender magnet
DE59501094D1 (de) Glovebox
DE69513743D1 (de) Magnet
DE69533366D1 (de) Radioaktivmarkierte annexin-galaktose-cluster konjugate
NO972868D0 (no) Oligonukleotid-dendrimer konjugater
DE9413768U1 (de) Kleinkoffer
DE29611617U1 (de) Abschirmung
KR950024232U (ko) 개량 권련 케이스
DE9418780U1 (de) Verteilerbauwerk
DE9400125U1 (de) Tisch-Fuß-Anordnung
KR960000099U (ko) 모기향 훈증기구
DE69414919D1 (de) Magnetlager
KR960024759U (ko) 자기헤드의 차폐 커버 조립 구조
KR960006746U (ko) 돈사용 덕트
SE9403235D0 (sv) Måtten
FI1222U1 (fi) Vaermeisolerande konstruktion
KR960019518U (ko) 실드 케이스의 구조
FI1369U1 (fi) Konstruktion till passagerarsaete
DE9421643U1 (de) Zirkulatoranordnung
KR960020015U (ko) 등 때밀이기
KR950026802U (ko) 분리조립식 개집
FI1547U1 (fi) Slirskydd foer bil

Legal Events

Date Code Title Description
8364 No opposition during term of opposition